Lucid Diagnostics Inc. (LUCD) Comparison with companies in other sectors?

Lucid Diagnostics Inc. has a share price of 108.19M. You can analyze Lucid Diagnostics Inc. (LUCD) competitors across different market sectors through stock heatmaps.

What are LUCD's NET and operating margins?

Lucid Diagnostics Inc. (LUCD) operating margin is around -15.06, and net profit margin is approximately -43.37 as of the latest reports.

In what way does LUCD's earnings per share (EPS) trend reflect its financial momentum?

Lucid Diagnostics Inc. (LUCD) EPS is -1.17 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Lucid Diagnostics Inc. is -0.94, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Lucid Diagnostics Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Lucid Diagnostics Inc. like P/E which is -0.00, P/B which is -0.01, and PEG which is 0.00. Compare them with sector averages to evaluate if the stock is priced fairly.

Lucid Diagnostics Inc.

LUCD•NASDAQ

Healthcare

Medical - Devices

$1.11

$0.01(0.91%)

Fundamental Analysis of Lucid Diagnostics Inc. (LUCD)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$-1.17

P/E Ratio

-0.94

ROE

26.96%

Net Margin

-43.37%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$119.56M

Shares OutstandingTotal number of shares issued

$108.19M

Book Value/ShareNet worth per share

$-78.16

Revenue/ShareAnnual revenue per share

$12.08

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-1.17

Net MarginNet income as percentage of revenue

-4336.70%

Operating MarginOperating income as percentage of revenue

-1506.27%

ROEReturn on shareholders' equity

2695.90%

ROAReturn on total assets

-109.93%

ROCEReturn on capital employed

331.80%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$-181.65

Cash/ShareCash and equivalents per share

$366.85

FCF YieldFree cash flow as percentage of market cap

-10453.04%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for LUCDFinancial Ratios Analysis details for LUCD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for LUCDSector Benchmarking details for LUCD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Lucid Diagnostics Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Lucid Diagnostics Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Lucid Diagnostics Inc.'s unique business strengths and challenges.

Key Financial Metrics for Lucid Diagnostics Inc.

For Lucid Diagnostics Inc., essential financial indicators include EPS -1.17, PE -0.94, and ROE 26.96. These key ratios reveal insights into Lucid Diagnostics Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Lucid Diagnostics Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Lucid Diagnostics Inc.

Metrics like Net Margin -4336.70% and ROA -109.93% shed light on how well Lucid Diagnostics Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Lucid Diagnostics Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Lucid Diagnostics Inc.

Using ratios such as P/B Ratio -0.01 and PEG Ratio 0.00, investors can assess whether Lucid Diagnostics Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Lucid Diagnostics Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Lucid Diagnostics Inc.

Financial health indicators, such as Debt/Equity Ratio -6.56 and Cash Flow $-181.65, provide a snapshot of Lucid Diagnostics Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Lucid Diagnostics Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Lucid Diagnostics Inc.

Investing in Lucid Diagnostics Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Lucid Diagnostics Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;